[PDF][PDF] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

GK Abou-Alfa, L Schwartz, S Ricci… - Journal of clinical …, 2006 - images.xinyao.com.cn
GK Abou-Alfa, L Schwartz, S Ricci, D Amadori, A Santoro, A Figer, J De Greve, JY Douillard…
Journal of clinical oncology, 2006images.xinyao.com.cn
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Page 1
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Ghassan K.
Abou-Alfa, Lawrence Schwartz, Sergio Ricci, Dino Amadori, Armando Santoro, Arie Figer,
Jacques De Greve, Jean-Yves Douillard, Chetan Lathia, Brian Schwartz, Ian Taylor, Marius
Moscovici, and Leonard B. Saltz A B S T R A C T Purpose This phase II study of sorafenib, an
oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed …
Purpose
This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients.
images.xinyao.com.cn